<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">35076930</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine-That is the Estimand.</ArticleTitle><Pagination><StartPage>817</StartPage><EndPage>825</EndPage><MedlinePgn>817-825</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.2533</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis is a rapidly progressive disease leading to death in, on average, 3-5&#xa0;years after first symptom onset. Consequently, there are frequently a non-negligible number of patients who die during the course of a clinical trial. This introduces bias in end points such as daily functioning, muscle strength, and quality of life. In this paper, we outline how the choice of strategy to handle death affects the interpretation of the trial results. We provide a general overview of the considerations, positioned in the estimand framework, and discuss the possibility that not every strategy provides a clinically relevant answer in each setting. The relevance of a strategy changes as a function of the intended trial duration, hypothesized treatment effect, and population included. It is important to consider this trade-off at the design stage of a clinical trial, as this will clarify the exact research question that is being answered, and better guide the planning, design, and analysis of the study.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science and Center for Innovative Study Design, School of Medicine, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roes</LastName><ForeName>Kit C B</ForeName><Initials>KCB</Initials><AffiliationInfo><Affiliation>Department of Health Evidence, Section Biostatistics, Radboud Medical Centre Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Greef-van der Sandt</LastName><ForeName>Inez</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Treeway BV, Tilburg, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science and Center for Innovative Study Design, School of Medicine, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL089778</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA124435</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declared no competing interests for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35076930</ArticleId><ArticleId IdType="mid">NIHMS1776143</ArticleId><ArticleId IdType="pmc">PMC8940672</ArticleId><ArticleId IdType="doi">10.1002/cpt.2533</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es, M.A. et al. Amyotrophic lateral sclerosis. Lancet 390, 2084&#x2013;2098 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, R.H. &amp; Al&#x2010;Chalabi, A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 162&#x2013;172 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto, H. , Brooks, B.R. &amp; Silani, V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 13, 1127&#x2013;1138 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg, L.H. et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 92, e1610&#x2013;e1623 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng, H.J. et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 17, 423&#x2013;433 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove, S.B. Clinical measures of disease progression in amyotrophic lateral sclerosis. Neurotherapeutics 12, 384&#x2013;393 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404434</ArticleId><ArticleId IdType="pubmed">25582382</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal, N.A. et al. Addressing heterogeneity in amyotrophic lateral sclerosis clinical trials. Muscle Nerve 62, 156&#x2013;166 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496557</ArticleId><ArticleId IdType="pubmed">31899540</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews, J.A. , Bruijn, L.I. &amp; Shefner, J.M. ALS drug development guidances and trial guidelines: consensus and opportunities for alignment. Neurology 93, 66&#x2013;71 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6656654</ArticleId><ArticleId IdType="pubmed">31171646</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk, R.P.A. , Kliest, T. &amp; van den Berg, L.H. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr. Opin. Neurol. 33, 655&#x2013;661 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32796282</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk, R.P.A. et al. Critical design considerations for time&#x2010;to&#x2010;event endpoints in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry 90, 1331&#x2013;1337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902062</ArticleId><ArticleId IdType="pubmed">31292200</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry, J.D. et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph. Lateral Scler. Frontotemporal. Degener. 14, 162&#x2013;168 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy, B.C. &amp; Schoenfeld, D. Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle Nerve 46, 506&#x2013;511 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22987690</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk, R.P.A. , Eijkemans, M.J.C. , Rizopoulos, D. , van den Berg, L.H. &amp; Nikolakopoulos, S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin. Epidemiol. 10, 333&#x2013;341 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865572</ArticleId><ArticleId IdType="pubmed">29593436</ArticleId></ArticleIdList></Reference><Reference><Citation>Daghlas, S.A. , Govindarajan, R. , &amp; Pooled Resource Open&#x2010;Access, A.L.S. Clinical Trials Consortium. Relative effects of forced vital capacity and ALSFRS&#x2010;R on survival in ALS. Muscle Nerve 64, 346&#x2013;351 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34076262</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruberg, S.J. &amp; Akacha, M. Considerations for evaluating treatment effects from randomized clinical trials. Clin. Pharmacol. Ther. 102, 917&#x2013;923 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28891044</ArticleId></ArticleIdList></Reference><Reference><Citation>Akacha, M. &amp; Kothny, W. Estimands: a more strategic approach to study design and analysis. Clin. Pharmacol. Ther. 102, 894&#x2013;896 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29119556</ArticleId></ArticleIdList></Reference><Reference><Citation>Akacha, M. , Bretz, F. &amp; Ruberg, S. Estimands in clinical trials &#x2010; broadening the perspective. Stat. Med. 36, 5&#x2013;19 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27435045</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;tavy, F. , Guizzaro, L. , Antunes dos Reis, I. , Teerenstra, S. &amp; Roes, K.C.B. Beyond &#x201c;Intent&#x2010;to&#x2010;treat&#x201d; and &#x201c;Per protocol&#x201d;: Improving assessment of treatment effects in clinical trials through the specification of an estimand. Br. J. Clin. Pharmacol. 86, 1235&#x2013;1239 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319001</ArticleId><ArticleId IdType="pubmed">31883123</ArticleId></ArticleIdList></Reference><Reference><Citation>
Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials: E9(R1)
. &lt;https://database.ICH.org/sites/default/files/E9&#x2010;R1_Step4_Guideline_2019_1203.pdf&gt; (2019). Accessed November 20, 2021.</Citation></Reference><Reference><Citation>Kahan, B.C. et al. Treatment estimands in clinical trials of patients hospitalised for COVID&#x2010;19: ensuring trials ask the right questions. BMC Med. 18, 286 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478913</ArticleId><ArticleId IdType="pubmed">32900372</ArticleId></ArticleIdList></Reference><Reference><Citation>Alemayehu, D. , Hemmings, R. , Natarajan, K. &amp; Roychoudhury, S. Perspectives on virtual (Remote) clinical trials as the "New Normal" to accelerate drug development. Clin. Pharmacol. Ther. 111, 373&#x2013;381 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">33792920</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiero, M.H. et al. Demystifying the estimand framework: a case study using patient&#x2010;reported outcomes in oncology. Lancet Oncol. 21, e488&#x2013;e494 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33002444</ArticleId></ArticleIdList></Reference><Reference><Citation>Oude Rengerink, K. , Mitroiu, M. , Teerenstra, S. , P&#xe9;tavy, F. &amp; Roes, K.C.B . Rethinking the intention&#x2010;to&#x2010;treat principle: one size does not fit all. J. Clin. Epidemiol. 125, 198&#x2013;200 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32380178</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidli, H. , Roger, J.H. &amp; Akacha, M. Estimands for recurrent event endpoints in the presence of a terminal event. Stat. Biopharm. Res. (2021).10.1080/19466315.2021.1895883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19466315.2021.1895883</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrance, R. et al. What is an estimand &amp; how does it relate to quantifying the effect of treatment on patient&#x2010;reported quality of life outcomes in clinical trials? J. Patient Rep. Outcomes 4, 68 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445213</ArticleId><ArticleId IdType="pubmed">32833083</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitroiu, M. , Oude Rengerink, K. , Teerenstra, S. , P&#xe9;tavy, F. &amp; Roes, K.C.B. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels? Trials 21, 671 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7376663</ArticleId><ArticleId IdType="pubmed">32703247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratitch, B. et al. Defining efficacy estimands in clinical trials: examples illustrating ICH E9(R1) guidelines. Ther. Innov. Regul. Sci. 54, 370&#x2013;384 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32072586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouanet, A. , Helmer, C. , Dartigues, J.&#x2010;F. &amp; Jacqmin&#x2010;Gadda, H. Interpretation of mixed models and marginal models with cohort attrition due to death and drop&#x2010;out. Stat. Methods Med. Res. 28, 343&#x2013;356 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">28784010</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a&#x2010;Hernandez, A. , P&#xe9;rez, T. , Pardo, M.D.C. &amp; Rizopoulos, D. MMRM vs joint modeling of longitudinal responses and time to study drug discontinuation in clinical trials using a "de jure" estimand. Pharm. Stat. 19, 909&#x2013;927 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32725810</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizopoulos, D. Joint models for longitudinal and time&#x2010;to&#x2010;event data: with applications in R (Chapman and Hall/CRC Press, Boca Raton, 2012).</Citation></Reference><Reference><Citation>Wulfsohn, M.S. &amp; Tsiatis, A.A. A joint model for survival and longitudinal data measured with error. Biometrics 53, 330&#x2013;339 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9147598</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI&#x2010;186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 16, 505&#x2013;512 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y.F. , Ni, X. , Fleisher, A.S. , Zhou, W. , Aisen, P. &amp; Mohs, R. A simulation study comparing slope model with mixed&#x2010;model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement. (NY) 4, 46&#x2013;53 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021263</ArticleId><ArticleId IdType="pubmed">29955651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashbeck, E.L. &amp; Bell, M.L. Single time point comparisons in longitudinal randomized controlled trials: power and bias in the presence of missing data. BMC Med. Res. Methodol. 16, 43 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828848</ArticleId><ArticleId IdType="pubmed">27068578</ArticleId></ArticleIdList></Reference><Reference><Citation>Keene, O.N. Strategies for composite estimands in confirmatory clinical trials: examples from trials in nasal polyps and steroid reduction. Pharm. Stat. 18, 78&#x2013;84 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30370691</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger, V. et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled, phase 2 trial. Lancet Neurol. 16, 208&#x2013;216 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28139349</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk, R.P.A. , van den Berg, L.H. &amp; Lu, Y. Composite endpoint for ALS clinical trials based on patient preference: Patient&#x2010;Ranked Order of Function (PROOF). J. Neurol. Neurosurg. Psychiatry (2021).10.1136/jnnp-2021-328194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-328194</ArticleId><ArticleId IdType="pmc">PMC9016230</ArticleId><ArticleId IdType="pubmed">34921121</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal, S.P. et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 9, 481&#x2013;488 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071495</ArticleId><ArticleId IdType="pubmed">20363190</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomadakis, C. , Meligkotsidou, L. , Pantazis, N. &amp; Touloumi, G. Longitudinal and time&#x2010;to&#x2010;drop&#x2010;out joint models can lead to seriously biased estimates when the drop&#x2010;out mechanism is at random. Biometrics 75, 58&#x2013;68 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30357814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz, M.E. et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double&#x2010;blind, phase 3 trial. Lancet Neurol. 12, 1059&#x2013;1067 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>